BioSig prices $15 million public offering of common stock

LOS ANGELES - BioSig Technologies, Inc. (NASDAQ:BSGM), a $80 million market cap company which recently merged with Streamex Exchange Corporation, announced Wednesday the pricing of its underwritten public offering of 3,852,149 shares of common stock at $3.90 per share. The stock has shown remarkable momentum, delivering over 200% returns year-to-date according to InvestingPro data.

The offering is expected to close around August 15, 2025, subject to customary closing conditions. Gross proceeds are anticipated to be approximately $15 million before deducting underwriter discounts, commissions, and other offering expenses. InvestingPro analysis indicates the company maintains a healthy current ratio of 2.37, suggesting strong ability to meet short-term obligations.

According to the company’s statement, BioSig plans to use the net proceeds to purchase gold bullion in accordance with its investment policy, as well as for working capital and general corporate purposes. With the stock trading at a significant Price/Book ratio of 48x and currently appearing overvalued based on InvestingPro Fair Value metrics, investors should conduct thorough due diligence. Get access to 13 additional exclusive ProTips and comprehensive financial analysis with InvestingPro.

Clear Street and Needham & Company are serving as joint book-running managers for the offering, which is being conducted pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission.

BioSig Technologies operates as both a medical device technology company with its PURE EP Platform for cardiovascular arrhythmia treatments and, through its Streamex subsidiary, focuses on gold tokenization and building infrastructure to bring the gold market on chain.

The announcement comes amid the company’s recent strategic shift following its merger with Streamex Exchange Corporation. The offering represents a significant capital raise for the newly combined entity as it pursues its business objectives in both the medical technology and gold tokenization sectors.

A final prospectus supplement relating to the offering will be filed with the SEC, according to the press release statement.

In other recent news, BioSig Technologies, Inc. announced its plans to conduct an underwritten public offering of common stock or pre-funded warrants. The company intends to use the proceeds to purchase gold bullion, aligning with its investment policy, as well as for working capital and general corporate purposes. Additionally, BioSig amended its debenture agreement with Yorkville, allowing for two secured convertible debentures, each valued at $25 million, with the potential for additional debentures totaling up to $50 million. This amendment also revised certain transaction terms, including the floor price for conversions.

In another development, BioSig’s subsidiary, Streamex Exchange Corporation, has engaged Compliance Exchange Group to manage the acquisition of a FINRA and SEC-registered broker-dealer. This acquisition aims to position Streamex as a pioneer in issuing regulated Real-World Asset tokens, focusing on gold-backed digital assets. Furthermore, Russell Starr has joined Streamex as a Strategic Advisor, bringing his expertise in capital markets and business development. BioSig also secured up to $1.1 billion in growth financing, including $100 million in senior secured convertible debentures and a $1 billion equity line of credit, to support its gold-backed treasury management strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.